Re: Seroxat ADR yellowcards =about 8 per 100,000 prescriptions

[Guest guest]

looks like Panorama show helped but the huge response

from the public

in yellow cards appears to be linked to the regulatory communications.

but if Panorama had not started the ball rolling would we have ever

gotten the

regulatory communications.

Interesting isn't it. Getting the MHRA or FDA to post a accurate

position on the

medications has the biggest effect on the public. In reverse we have

the public

gobbling up these nasty toxins if the regulatory agencies say the drugs

are safe.

Solution: Fix the regulatory agencies since they are blindly followed

by the public.

On 2/2/2010 5:16 AM, jeremy9282 wrote:

Suspected adverse

drug reactions to paroxetine (yellow-card reports) per 100 000

paroxetine prescriptions by year and month between 2001 and 2004.

Arrows indicate dates of Panorama programmes (solid arrows) or

regulatory communications (dashed arrows)

Br J Clin Pharmacol. 2006 February; 61(2): 224–228.

Published online 2005 October 27. doi: 10.1111/j.1365-2125.2005.02527.

[Guest guest]

Hi Jim

I have no doubt that the Publication of Panorama led to increases in yellowcard reporting on Seroxat (Paxil) but one also has to look at the other consequences.

The Chart below shows that while Seroxat sales declined after the publication of Panorama the sales of the other brands actually increases.

The general view amongst people in my country is that Seroxat = bad .........all other SSRI = useful/harmless.

Interesting though it is to see the MHRA/FDA do something about Paxil/Seroxat it is so sad to see how little they do with the other brands which the public swallow with gay abandon.

Regards

see -

Prescribing of paroxetine was relatively steady between January 2001 and April 2002, but there was strong evidence that the number of paroxetine items prescribed per month declined after April 2002 [95% confidence interval (CI) December 2001 to June 2002] (P < 0.0001 for test of null hypothesis that difference between first and second slope = 0), so that the estimated monthly percentage change after this time was -1.87% (95% CI -2.06, -1.68; P < 0.0001 for test of null hypothesis that monthly percentage change = 0) (Figure 1A). There was no evidence that the rate of decline in prescribing of paroxetine changed again up to November 2004.

In contrast, prescribing of all other SSRIs combined (mainly fluoxetine and citalopram) increased by 1.15% (95% CI 1.01, 1.29; P ¡Ü 0.0001) per month between January 2001 and December 2003. After December 2003 the rate of increase declined (0.33%; 95% CI -0.39; 1.05; P = 0.4) (P = 0.03, for difference between slope 1 and 2) (Figure 1B), although the 95% CI for a join point at December 2003 was wide (April 2002 to June 2004).

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884992/

> >> >> >> >> > Suspected adverse drug reactions to paroxetine (yellow-card reports) > > per 100 000 paroxetine prescriptions by year and month between 2001 > > and 2004. Arrows indicate dates of Panorama programmes (solid arrows) > > or regulatory communications (dashed arrows)> >> >> > Br J Clin Pharmacol. 2006 February; 61(2): 224--228.> >> > Published online 2005 October 27. doi: 10.1111/j.1365-2125.2005.02527.> >> >>

[Guest guest]

Hi Jim

I have no doubt that the Publication of Panorama led to increases in yellowcard reporting on Seroxat (Paxil) but one also has to look at the other consequences.

The Chart below shows that while Seroxat sales declined after the publication of Panorama the sales of the other brands actually increases.

The general view amongst people in my country is that Seroxat = bad .........all other SSRI = useful/harmless.

Interesting though it is to see the MHRA/FDA do something about Paxil/Seroxat it is so sad to see how little they do with the other brands which the public swallow with gay abandon.

Regards

see -

Prescribing of paroxetine was relatively steady between January 2001 and April 2002, but there was strong evidence that the number of paroxetine items prescribed per month declined after April 2002 [95% confidence interval (CI) December 2001 to June 2002] (P < 0.0001 for test of null hypothesis that difference between first and second slope = 0), so that the estimated monthly percentage change after this time was -1.87% (95% CI -2.06, -1.68; P < 0.0001 for test of null hypothesis that monthly percentage change = 0) (Figure 1A). There was no evidence that the rate of decline in prescribing of paroxetine changed again up to November 2004.

In contrast, prescribing of all other SSRIs combined (mainly fluoxetine and citalopram) increased by 1.15% (95% CI 1.01, 1.29; P ¡Ü 0.0001) per month between January 2001 and December 2003. After December 2003 the rate of increase declined (0.33%; 95% CI -0.39; 1.05; P = 0.4) (P = 0.03, for difference between slope 1 and 2) (Figure 1B), although the 95% CI for a join point at December 2003 was wide (April 2002 to June 2004).

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884992/

> >> >> >> >> > Suspected adverse drug reactions to paroxetine (yellow-card reports) > > per 100 000 paroxetine prescriptions by year and month between 2001 > > and 2004. Arrows indicate dates of Panorama programmes (solid arrows) > > or regulatory communications (dashed arrows)> >> >> > Br J Clin Pharmacol. 2006 February; 61(2): 224--228.> >> > Published online 2005 October 27. doi: 10.1111/j.1365-2125.2005.02527.> >> >>

[Guest guest]

Hi Jim

I have no doubt that the Publication of Panorama led to increases in yellowcard reporting on Seroxat (Paxil) but one also has to look at the other consequences.

The Chart below shows that while Seroxat sales declined after the publication of Panorama the sales of the other brands actually increases.

The general view amongst people in my country is that Seroxat = bad .........all other SSRI = useful/harmless.

Interesting though it is to see the MHRA/FDA do something about Paxil/Seroxat it is so sad to see how little they do with the other brands which the public swallow with gay abandon.

Regards

see -

Prescribing of paroxetine was relatively steady between January 2001 and April 2002, but there was strong evidence that the number of paroxetine items prescribed per month declined after April 2002 [95% confidence interval (CI) December 2001 to June 2002] (P < 0.0001 for test of null hypothesis that difference between first and second slope = 0), so that the estimated monthly percentage change after this time was -1.87% (95% CI -2.06, -1.68; P < 0.0001 for test of null hypothesis that monthly percentage change = 0) (Figure 1A). There was no evidence that the rate of decline in prescribing of paroxetine changed again up to November 2004.

In contrast, prescribing of all other SSRIs combined (mainly fluoxetine and citalopram) increased by 1.15% (95% CI 1.01, 1.29; P ¡Ü 0.0001) per month between January 2001 and December 2003. After December 2003 the rate of increase declined (0.33%; 95% CI -0.39; 1.05; P = 0.4) (P = 0.03, for difference between slope 1 and 2) (Figure 1B), although the 95% CI for a join point at December 2003 was wide (April 2002 to June 2004).

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884992/

> >> >> >> >> > Suspected adverse drug reactions to paroxetine (yellow-card reports) > > per 100 000 paroxetine prescriptions by year and month between 2001 > > and 2004. Arrows indicate dates of Panorama programmes (solid arrows) > > or regulatory communications (dashed arrows)> >> >> > Br J Clin Pharmacol. 2006 February; 61(2): 224--228.> >> > Published online 2005 October 27. doi: 10.1111/j.1365-2125.2005.02527.> >> >>

[Guest guest]

Hi Jim

I have no doubt that the Publication of Panorama led to increases in yellowcard reporting on Seroxat (Paxil) but one also has to look at the other consequences.

The Chart below shows that while Seroxat sales declined after the publication of Panorama the sales of the other brands actually increases.

The general view amongst people in my country is that Seroxat = bad .........all other SSRI = useful/harmless.

Interesting though it is to see the MHRA/FDA do something about Paxil/Seroxat it is so sad to see how little they do with the other brands which the public swallow with gay abandon.

Regards

see -

Prescribing of paroxetine was relatively steady between January 2001 and April 2002, but there was strong evidence that the number of paroxetine items prescribed per month declined after April 2002 [95% confidence interval (CI) December 2001 to June 2002] (P < 0.0001 for test of null hypothesis that difference between first and second slope = 0), so that the estimated monthly percentage change after this time was -1.87% (95% CI -2.06, -1.68; P < 0.0001 for test of null hypothesis that monthly percentage change = 0) (Figure 1A). There was no evidence that the rate of decline in prescribing of paroxetine changed again up to November 2004.

In contrast, prescribing of all other SSRIs combined (mainly fluoxetine and citalopram) increased by 1.15% (95% CI 1.01, 1.29; P ¡Ü 0.0001) per month between January 2001 and December 2003. After December 2003 the rate of increase declined (0.33%; 95% CI -0.39; 1.05; P = 0.4) (P = 0.03, for difference between slope 1 and 2) (Figure 1B), although the 95% CI for a join point at December 2003 was wide (April 2002 to June 2004).

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884992/

> >> >> >> >> > Suspected adverse drug reactions to paroxetine (yellow-card reports) > > per 100 000 paroxetine prescriptions by year and month between 2001 > > and 2004. Arrows indicate dates of Panorama programmes (solid arrows) > > or regulatory communications (dashed arrows)> >> >> > Br J Clin Pharmacol. 2006 February; 61(2): 224--228.> >> > Published online 2005 October 27. doi: 10.1111/j.1365-2125.2005.02527.> >> >>

[Guest guest]

Hi ,

I agree it's a sad fact. Seroxat is the worst in my opinion but

obviously the rest are bad also and a huge potential

risk to even be considered.

Both MHRA and FDA should reevaluate the data with the new studies and

pull the drugs. The FDA is worthless in that

regard.

Sadly since the medical field insists on drugging then if one drug gets

the bad press then the others will fill the vacuum.

Best,

Jim

On 2/3/2010 3:40 AM, jeremy9282 wrote:

Hi Jim

I have no doubt that the Publication of Panorama led to increases

in yellowcard reporting on Seroxat (Paxil) but one also has to look at

the other consequences.

The Chart below shows that while Seroxat sales declined after the

publication of Panorama the sales of the other brands actually

increases.

The general view amongst people in my country is that Seroxat =

bad .........all other SSRI = useful/harmless.

Interesting though it is to see the MHRA/FDA do something about

Paxil/Seroxat it is so sad to see how little they do with the other

brands which the public swallow with gay abandon.

Regards

see -

Prescribing of paroxetine was relatively steady

between January 2001 and April 2002, but there was strong evidence that

the number of paroxetine items prescribed per month declined after

April 2002 [95% confidence interval (CI) December 2001 to June 2002] (P

< 0.0001 for test of null hypothesis that difference between first

and second slope = 0), so that the estimated monthly percentage change

after this time was -1.87% (95% CI -2.06, -1.68; P < 0.0001 for test

of null hypothesis that monthly percentage change = 0) (Figure 1A).

There was no evidence that the rate of decline in prescribing of

paroxetine changed again up to November 2004.

In

contrast, prescribing of all other SSRIs combined (mainly fluoxetine

and citalopram) increased by 1.15% (95% CI 1.01, 1.29; P ¡Ü 0.0001) per

month between January 2001 and December 2003. After December 2003 the

rate of increase declined (0.33%; 95% CI -0.39; 1.05; P = 0.4) (P =

0.03, for difference between slope 1 and 2) (Figure 1B), although the

95% CI for a join point at December 2003 was wide (April 2002 to June

2004).

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884992/

> >

> >

> >

> >

> > Suspected adverse drug reactions to paroxetine (yellow-card

reports)

> > per 100 000 paroxetine prescriptions by year and month

between 2001

> > and 2004. Arrows indicate dates of Panorama programmes (solid

arrows)

> > or regulatory communications (dashed arrows)

> >

> >

> > Br J Clin Pharmacol. 2006 February; 61(2): 224--228.

> >

> > Published online 2005 October 27. doi:

10.1111/j.1365-2125.2005.02527.

> >

> >

>

[Guest guest]

Hi ,

I agree it's a sad fact. Seroxat is the worst in my opinion but

obviously the rest are bad also and a huge potential

risk to even be considered.

Both MHRA and FDA should reevaluate the data with the new studies and

pull the drugs. The FDA is worthless in that

regard.

Sadly since the medical field insists on drugging then if one drug gets

the bad press then the others will fill the vacuum.

Best,

Jim

On 2/3/2010 3:40 AM, jeremy9282 wrote:

Hi Jim

I have no doubt that the Publication of Panorama led to increases

in yellowcard reporting on Seroxat (Paxil) but one also has to look at

the other consequences.

The Chart below shows that while Seroxat sales declined after the

publication of Panorama the sales of the other brands actually

increases.

The general view amongst people in my country is that Seroxat =

bad .........all other SSRI = useful/harmless.

Interesting though it is to see the MHRA/FDA do something about

Paxil/Seroxat it is so sad to see how little they do with the other

brands which the public swallow with gay abandon.

Regards

see -

Prescribing of paroxetine was relatively steady

between January 2001 and April 2002, but there was strong evidence that

the number of paroxetine items prescribed per month declined after

April 2002 [95% confidence interval (CI) December 2001 to June 2002] (P

< 0.0001 for test of null hypothesis that difference between first

and second slope = 0), so that the estimated monthly percentage change

after this time was -1.87% (95% CI -2.06, -1.68; P < 0.0001 for test

of null hypothesis that monthly percentage change = 0) (Figure 1A).

There was no evidence that the rate of decline in prescribing of

paroxetine changed again up to November 2004.

In

contrast, prescribing of all other SSRIs combined (mainly fluoxetine

and citalopram) increased by 1.15% (95% CI 1.01, 1.29; P ¡Ü 0.0001) per

month between January 2001 and December 2003. After December 2003 the

rate of increase declined (0.33%; 95% CI -0.39; 1.05; P = 0.4) (P =

0.03, for difference between slope 1 and 2) (Figure 1B), although the

95% CI for a join point at December 2003 was wide (April 2002 to June

2004).

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884992/

> >

> >

> >

> >

> > Suspected adverse drug reactions to paroxetine (yellow-card

reports)

> > per 100 000 paroxetine prescriptions by year and month

between 2001

> > and 2004. Arrows indicate dates of Panorama programmes (solid

arrows)

> > or regulatory communications (dashed arrows)

> >

> >

> > Br J Clin Pharmacol. 2006 February; 61(2): 224--228.

> >

> > Published online 2005 October 27. doi:

10.1111/j.1365-2125.2005.02527.

> >

> >

>

[Guest guest]

Hi ,

I agree it's a sad fact. Seroxat is the worst in my opinion but

obviously the rest are bad also and a huge potential

risk to even be considered.

Both MHRA and FDA should reevaluate the data with the new studies and

pull the drugs. The FDA is worthless in that

regard.

Sadly since the medical field insists on drugging then if one drug gets

the bad press then the others will fill the vacuum.

Best,

Jim

On 2/3/2010 3:40 AM, jeremy9282 wrote:

Hi Jim

I have no doubt that the Publication of Panorama led to increases

in yellowcard reporting on Seroxat (Paxil) but one also has to look at

the other consequences.

The Chart below shows that while Seroxat sales declined after the

publication of Panorama the sales of the other brands actually

increases.

The general view amongst people in my country is that Seroxat =

bad .........all other SSRI = useful/harmless.

Interesting though it is to see the MHRA/FDA do something about

Paxil/Seroxat it is so sad to see how little they do with the other

brands which the public swallow with gay abandon.

Regards

see -

Prescribing of paroxetine was relatively steady

between January 2001 and April 2002, but there was strong evidence that

the number of paroxetine items prescribed per month declined after

April 2002 [95% confidence interval (CI) December 2001 to June 2002] (P

< 0.0001 for test of null hypothesis that difference between first

and second slope = 0), so that the estimated monthly percentage change

after this time was -1.87% (95% CI -2.06, -1.68; P < 0.0001 for test

of null hypothesis that monthly percentage change = 0) (Figure 1A).

There was no evidence that the rate of decline in prescribing of

paroxetine changed again up to November 2004.

In

contrast, prescribing of all other SSRIs combined (mainly fluoxetine

and citalopram) increased by 1.15% (95% CI 1.01, 1.29; P ¡Ü 0.0001) per

month between January 2001 and December 2003. After December 2003 the

rate of increase declined (0.33%; 95% CI -0.39; 1.05; P = 0.4) (P =

0.03, for difference between slope 1 and 2) (Figure 1B), although the

95% CI for a join point at December 2003 was wide (April 2002 to June

2004).

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884992/

> >

> >

> >

> >

> > Suspected adverse drug reactions to paroxetine (yellow-card

reports)

> > per 100 000 paroxetine prescriptions by year and month

between 2001

> > and 2004. Arrows indicate dates of Panorama programmes (solid

arrows)

> > or regulatory communications (dashed arrows)

> >

> >

> > Br J Clin Pharmacol. 2006 February; 61(2): 224--228.

> >

> > Published online 2005 October 27. doi:

10.1111/j.1365-2125.2005.02527.

> >

> >

>

[Guest guest]

Hi ,

I agree it's a sad fact. Seroxat is the worst in my opinion but

obviously the rest are bad also and a huge potential

risk to even be considered.

Both MHRA and FDA should reevaluate the data with the new studies and

pull the drugs. The FDA is worthless in that

regard.

Sadly since the medical field insists on drugging then if one drug gets

the bad press then the others will fill the vacuum.

Best,

Jim

On 2/3/2010 3:40 AM, jeremy9282 wrote:

Hi Jim

I have no doubt that the Publication of Panorama led to increases

in yellowcard reporting on Seroxat (Paxil) but one also has to look at

the other consequences.

The Chart below shows that while Seroxat sales declined after the

publication of Panorama the sales of the other brands actually

increases.

The general view amongst people in my country is that Seroxat =

bad .........all other SSRI = useful/harmless.

Interesting though it is to see the MHRA/FDA do something about

Paxil/Seroxat it is so sad to see how little they do with the other

brands which the public swallow with gay abandon.

Regards

see -

Prescribing of paroxetine was relatively steady

between January 2001 and April 2002, but there was strong evidence that

the number of paroxetine items prescribed per month declined after

April 2002 [95% confidence interval (CI) December 2001 to June 2002] (P

< 0.0001 for test of null hypothesis that difference between first

and second slope = 0), so that the estimated monthly percentage change

after this time was -1.87% (95% CI -2.06, -1.68; P < 0.0001 for test

of null hypothesis that monthly percentage change = 0) (Figure 1A).

There was no evidence that the rate of decline in prescribing of

paroxetine changed again up to November 2004.

In

contrast, prescribing of all other SSRIs combined (mainly fluoxetine

and citalopram) increased by 1.15% (95% CI 1.01, 1.29; P ¡Ü 0.0001) per

month between January 2001 and December 2003. After December 2003 the

rate of increase declined (0.33%; 95% CI -0.39; 1.05; P = 0.4) (P =

0.03, for difference between slope 1 and 2) (Figure 1B), although the

95% CI for a join point at December 2003 was wide (April 2002 to June

2004).

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884992/

> >

> >

> >

> >

> > Suspected adverse drug reactions to paroxetine (yellow-card

reports)

> > per 100 000 paroxetine prescriptions by year and month

between 2001

> > and 2004. Arrows indicate dates of Panorama programmes (solid

arrows)

> > or regulatory communications (dashed arrows)

> >

> >

> > Br J Clin Pharmacol. 2006 February; 61(2): 224--228.

> >

> > Published online 2005 October 27. doi:

10.1111/j.1365-2125.2005.02527.

> >

> >

>

[Guest guest]

Two people die from faulty brake pedals, and the NTSB pulls cars off the road. Millions of lives destroyed, and hundreds die every day from the chemical poisons, which are never even winced at.

Hi Jim

I have no doubt that the Publication of Panorama led to increases in yellowcard reporting on Seroxat (Paxil) but one also has to look at the other consequences.

The Chart below shows that while Seroxat sales declined after the publication of Panorama the sales of the other brands actually increases.

The general view amongst people in my country is that Seroxat = bad .........all other SSRI = useful/harmless.

Interesting though it is to see the MHRA/FDA do something about Paxil/Seroxat it is so sad to see how little they do with the other brands which the public swallow with gay abandon.

Regards

see -

Prescribing of paroxetine was relatively steady between January 2001 and April 2002, but there was strong evidence that the number of paroxetine items prescribed per month declined after April 2002 [95% confidence interval (CI) December 2001 to June 2002] (P < 0.0001 for test of null hypothesis that difference between first and second slope = 0), so that the estimated monthly percentage change after this time was -1.87% (95% CI -2.06, -1.68; P < 0.0001 for test of null hypothesis that monthly percentage change = 0) (Figure 1A). There was no evidence that the rate of decline in prescribing of paroxetine changed again up to November 2004.

In contrast, prescribing of all other SSRIs combined (mainly fluoxetine and citalopram) increased by 1.15% (95% CI 1.01, 1.29; P ¡Ü 0.0001) per month between January 2001 and December 2003. After December 2003 the rate of increase declined (0.33%; 95% CI -0.39; 1.05; P = 0.4) (P = 0.03, for difference between slope 1 and 2) (Figure 1B), although the 95% CI for a join point at December 2003 was wide (April 2002 to June 2004).

http://www.ncbi. nlm.nih.gov/ pmc/articles/ PMC1884992/

> >> >> >> >> > Suspected adverse drug reactions to paroxetine (yellow-card reports) > > per 100 000 paroxetine prescriptions by year and month between 2001 > > and 2004. Arrows indicate dates of Panorama programmes (solid arrows) > > or regulatory communications (dashed arrows)> >> >> > Br J Clin Pharmacol. 2006 February; 61(2): 224--228.> >> > Published online 2005 October 27. doi: 10.1111/j.1365- 2125.2005. 02527.> >> >>

[Guest guest]

Two people die from faulty brake pedals, and the NTSB pulls cars off the road. Millions of lives destroyed, and hundreds die every day from the chemical poisons, which are never even winced at.

Hi Jim

I have no doubt that the Publication of Panorama led to increases in yellowcard reporting on Seroxat (Paxil) but one also has to look at the other consequences.

The Chart below shows that while Seroxat sales declined after the publication of Panorama the sales of the other brands actually increases.

The general view amongst people in my country is that Seroxat = bad .........all other SSRI = useful/harmless.

Interesting though it is to see the MHRA/FDA do something about Paxil/Seroxat it is so sad to see how little they do with the other brands which the public swallow with gay abandon.

Regards

see -

Prescribing of paroxetine was relatively steady between January 2001 and April 2002, but there was strong evidence that the number of paroxetine items prescribed per month declined after April 2002 [95% confidence interval (CI) December 2001 to June 2002] (P < 0.0001 for test of null hypothesis that difference between first and second slope = 0), so that the estimated monthly percentage change after this time was -1.87% (95% CI -2.06, -1.68; P < 0.0001 for test of null hypothesis that monthly percentage change = 0) (Figure 1A). There was no evidence that the rate of decline in prescribing of paroxetine changed again up to November 2004.

In contrast, prescribing of all other SSRIs combined (mainly fluoxetine and citalopram) increased by 1.15% (95% CI 1.01, 1.29; P ¡Ü 0.0001) per month between January 2001 and December 2003. After December 2003 the rate of increase declined (0.33%; 95% CI -0.39; 1.05; P = 0.4) (P = 0.03, for difference between slope 1 and 2) (Figure 1B), although the 95% CI for a join point at December 2003 was wide (April 2002 to June 2004).

http://www.ncbi. nlm.nih.gov/ pmc/articles/ PMC1884992/

> >> >> >> >> > Suspected adverse drug reactions to paroxetine (yellow-card reports) > > per 100 000 paroxetine prescriptions by year and month between 2001 > > and 2004. Arrows indicate dates of Panorama programmes (solid arrows) > > or regulatory communications (dashed arrows)> >> >> > Br J Clin Pharmacol. 2006 February; 61(2): 224--228.> >> > Published online 2005 October 27. doi: 10.1111/j.1365- 2125.2005. 02527.> >> >>

[Guest guest]

Two people die from faulty brake pedals, and the NTSB pulls cars off the road. Millions of lives destroyed, and hundreds die every day from the chemical poisons, which are never even winced at.

Hi Jim

I have no doubt that the Publication of Panorama led to increases in yellowcard reporting on Seroxat (Paxil) but one also has to look at the other consequences.

The Chart below shows that while Seroxat sales declined after the publication of Panorama the sales of the other brands actually increases.

The general view amongst people in my country is that Seroxat = bad .........all other SSRI = useful/harmless.

Interesting though it is to see the MHRA/FDA do something about Paxil/Seroxat it is so sad to see how little they do with the other brands which the public swallow with gay abandon.

Regards

see -

Prescribing of paroxetine was relatively steady between January 2001 and April 2002, but there was strong evidence that the number of paroxetine items prescribed per month declined after April 2002 [95% confidence interval (CI) December 2001 to June 2002] (P < 0.0001 for test of null hypothesis that difference between first and second slope = 0), so that the estimated monthly percentage change after this time was -1.87% (95% CI -2.06, -1.68; P < 0.0001 for test of null hypothesis that monthly percentage change = 0) (Figure 1A). There was no evidence that the rate of decline in prescribing of paroxetine changed again up to November 2004.

In contrast, prescribing of all other SSRIs combined (mainly fluoxetine and citalopram) increased by 1.15% (95% CI 1.01, 1.29; P ¡Ü 0.0001) per month between January 2001 and December 2003. After December 2003 the rate of increase declined (0.33%; 95% CI -0.39; 1.05; P = 0.4) (P = 0.03, for difference between slope 1 and 2) (Figure 1B), although the 95% CI for a join point at December 2003 was wide (April 2002 to June 2004).

http://www.ncbi. nlm.nih.gov/ pmc/articles/ PMC1884992/

> >> >> >> >> > Suspected adverse drug reactions to paroxetine (yellow-card reports) > > per 100 000 paroxetine prescriptions by year and month between 2001 > > and 2004. Arrows indicate dates of Panorama programmes (solid arrows) > > or regulatory communications (dashed arrows)> >> >> > Br J Clin Pharmacol. 2006 February; 61(2): 224--228.> >> > Published online 2005 October 27. doi: 10.1111/j.1365- 2125.2005. 02527.> >> >>

[Guest guest]

Two people die from faulty brake pedals, and the NTSB pulls cars off the road. Millions of lives destroyed, and hundreds die every day from the chemical poisons, which are never even winced at.

Hi Jim

I have no doubt that the Publication of Panorama led to increases in yellowcard reporting on Seroxat (Paxil) but one also has to look at the other consequences.

The Chart below shows that while Seroxat sales declined after the publication of Panorama the sales of the other brands actually increases.

The general view amongst people in my country is that Seroxat = bad .........all other SSRI = useful/harmless.

Interesting though it is to see the MHRA/FDA do something about Paxil/Seroxat it is so sad to see how little they do with the other brands which the public swallow with gay abandon.

Regards

see -

Prescribing of paroxetine was relatively steady between January 2001 and April 2002, but there was strong evidence that the number of paroxetine items prescribed per month declined after April 2002 [95% confidence interval (CI) December 2001 to June 2002] (P < 0.0001 for test of null hypothesis that difference between first and second slope = 0), so that the estimated monthly percentage change after this time was -1.87% (95% CI -2.06, -1.68; P < 0.0001 for test of null hypothesis that monthly percentage change = 0) (Figure 1A). There was no evidence that the rate of decline in prescribing of paroxetine changed again up to November 2004.

In contrast, prescribing of all other SSRIs combined (mainly fluoxetine and citalopram) increased by 1.15% (95% CI 1.01, 1.29; P ¡Ü 0.0001) per month between January 2001 and December 2003. After December 2003 the rate of increase declined (0.33%; 95% CI -0.39; 1.05; P = 0.4) (P = 0.03, for difference between slope 1 and 2) (Figure 1B), although the 95% CI for a join point at December 2003 was wide (April 2002 to June 2004).

http://www.ncbi. nlm.nih.gov/ pmc/articles/ PMC1884992/

> >> >> >> >> > Suspected adverse drug reactions to paroxetine (yellow-card reports) > > per 100 000 paroxetine prescriptions by year and month between 2001 > > and 2004. Arrows indicate dates of Panorama programmes (solid arrows) > > or regulatory communications (dashed arrows)> >> >> > Br J Clin Pharmacol. 2006 February; 61(2): 224--228.> >> > Published online 2005 October 27. doi: 10.1111/j.1365- 2125.2005. 02527.> >> >>

[Guest guest]

Hi Jim

I was wondering on what you base your personal opinion that Paxil/Seroxat is the worse?

I'm very concerned that the (UK) media, led by Panorama have broadcast that view, when it is clear that the producers of the programme chose to target the GSK product, even though journalists like Jofre are on record as saying all the brands have similar problems.

check her out here - http://coventryuniversity.podbean.com/2007/11/01/one-woman-a-multinational-and-a-victory-shelley-jofre-panorama/

Could the adverse publicity surrounding Paxil/Seroxat have made the total SSRI situation worse?

see -http://www.tuesday1st.blogspot.com/

Regards

> > > >> > > >> > > >> > > >> > > > Suspected adverse drug reactions to paroxetine (yellow-card reports)> > > > per 100 000 paroxetine prescriptions by year and month between 2001> > > > and 2004. Arrows indicate dates of Panorama programmes (solid arrows)> > > > or regulatory communications (dashed arrows)> > > >> > > >> > > > Br J Clin Pharmacol. 2006 February; 61(2): 224--228.> > > >> > > > Published online 2005 October 27. doi: 10.1111/j.1365-2125.2005.02527.> > > >> > > >> > >> >> >> >> >>

[Guest guest]

Hi Jim

I was wondering on what you base your personal opinion that Paxil/Seroxat is the worse?

I'm very concerned that the (UK) media, led by Panorama have broadcast that view, when it is clear that the producers of the programme chose to target the GSK product, even though journalists like Jofre are on record as saying all the brands have similar problems.

check her out here - http://coventryuniversity.podbean.com/2007/11/01/one-woman-a-multinational-and-a-victory-shelley-jofre-panorama/

Could the adverse publicity surrounding Paxil/Seroxat have made the total SSRI situation worse?

see -http://www.tuesday1st.blogspot.com/

Regards

> > > >> > > >> > > >> > > >> > > > Suspected adverse drug reactions to paroxetine (yellow-card reports)> > > > per 100 000 paroxetine prescriptions by year and month between 2001> > > > and 2004. Arrows indicate dates of Panorama programmes (solid arrows)> > > > or regulatory communications (dashed arrows)> > > >> > > >> > > > Br J Clin Pharmacol. 2006 February; 61(2): 224--228.> > > >> > > > Published online 2005 October 27. doi: 10.1111/j.1365-2125.2005.02527.> > > >> > > >> > >> >> >> >> >>

[Guest guest]

Hi Jim

I was wondering on what you base your personal opinion that Paxil/Seroxat is the worse?

I'm very concerned that the (UK) media, led by Panorama have broadcast that view, when it is clear that the producers of the programme chose to target the GSK product, even though journalists like Jofre are on record as saying all the brands have similar problems.

check her out here - http://coventryuniversity.podbean.com/2007/11/01/one-woman-a-multinational-and-a-victory-shelley-jofre-panorama/

Could the adverse publicity surrounding Paxil/Seroxat have made the total SSRI situation worse?

see -http://www.tuesday1st.blogspot.com/

Regards

> > > >> > > >> > > >> > > >> > > > Suspected adverse drug reactions to paroxetine (yellow-card reports)> > > > per 100 000 paroxetine prescriptions by year and month between 2001> > > > and 2004. Arrows indicate dates of Panorama programmes (solid arrows)> > > > or regulatory communications (dashed arrows)> > > >> > > >> > > > Br J Clin Pharmacol. 2006 February; 61(2): 224--228.> > > >> > > > Published online 2005 October 27. doi: 10.1111/j.1365-2125.2005.02527.> > > >> > > >> > >> >> >> >> >>

[Guest guest]

Hi Jim

I was wondering on what you base your personal opinion that Paxil/Seroxat is the worse?

I'm very concerned that the (UK) media, led by Panorama have broadcast that view, when it is clear that the producers of the programme chose to target the GSK product, even though journalists like Jofre are on record as saying all the brands have similar problems.

check her out here - http://coventryuniversity.podbean.com/2007/11/01/one-woman-a-multinational-and-a-victory-shelley-jofre-panorama/

Could the adverse publicity surrounding Paxil/Seroxat have made the total SSRI situation worse?

see -http://www.tuesday1st.blogspot.com/

Regards

> > > >> > > >> > > >> > > >> > > > Suspected adverse drug reactions to paroxetine (yellow-card reports)> > > > per 100 000 paroxetine prescriptions by year and month between 2001> > > > and 2004. Arrows indicate dates of Panorama programmes (solid arrows)> > > > or regulatory communications (dashed arrows)> > > >> > > >> > > > Br J Clin Pharmacol. 2006 February; 61(2): 224--228.> > > >> > > > Published online 2005 October 27. doi: 10.1111/j.1365-2125.2005.02527.> > > >> > > >> > >> >> >> >> >>

[Guest guest]

my thoughts exactely....

In memory of my father. Effexor (the loaded gun)

From: Antony Sandler <antonysandler@...>SSRI medications Sent: Wed, February 3, 2010 12:36:49 PMSubject: Re: Re: Seroxat ADR yellowcards =about 8 per 100,000 prescriptions

Two people die from faulty brake pedals, and the NTSB pulls cars off the road. Millions of lives destroyed, and hundreds die every day from the chemical poisons, which are never even winced at.

Hi Jim

I have no doubt that the Publication of Panorama led to increases in yellowcard reporting on Seroxat (Paxil) but one also has to look at the other consequences.

The Chart below shows that while Seroxat sales declined after the publication of Panorama the sales of the other brands actually increases.

The general view amongst people in my country is that Seroxat = bad .........all other SSRI = useful/harmless.

Interesting though it is to see the MHRA/FDA do something about Paxil/Seroxat it is so sad to see how little they do with the other brands which the public swallow with gay abandon.

Regards

see -

Prescribing of paroxetine was relatively steady between January 2001 and April 2002, but there was strong evidence that the number of paroxetine items prescribed per month declined after April 2002 [95% confidence interval (CI) December 2001 to June 2002] (P < 0.0001 for test of null hypothesis that difference between first and second slope = 0), so that the estimated monthly percentage change after this time was -1.87% (95% CI -2.06, -1.68; P < 0.0001 for test of null hypothesis that monthly percentage change = 0) (Figure 1A). There was no evidence that the rate of decline in prescribing of paroxetine changed again up to November 2004.

In contrast, prescribing of all other SSRIs combined (mainly fluoxetine and citalopram) increased by 1.15% (95% CI 1.01, 1.29; P ¡Ü 0.0001) per month between January 2001 and December 2003. After December 2003 the rate of increase declined (0.33%; 95% CI -0.39; 1.05; P = 0.4) (P = 0.03, for difference between slope 1 and 2) (Figure 1B), although the 95% CI for a join point at December 2003 was wide (April 2002 to June 2004).

http://www.ncbi. nlm.nih.gov/ pmc/articles/ PMC1884992/

> >> >> >> >> > Suspected adverse drug reactions to paroxetine (yellow-card reports) > > per 100 000 paroxetine prescriptions by year and month between 2001 > > and 2004. Arrows indicate dates of Panorama programmes (solid arrows) > > or regulatory communications (dashed arrows)> >> >> > Br J Clin Pharmacol. 2006 February; 61(2): 224--228.> >> > Published online 2005 October 27. doi: 10.1111/j.1365- 2125.2005. 02527.> >> >>

[Guest guest]

my thoughts exactely....

In memory of my father. Effexor (the loaded gun)

From: Antony Sandler <antonysandler@...>SSRI medications Sent: Wed, February 3, 2010 12:36:49 PMSubject: Re: Re: Seroxat ADR yellowcards =about 8 per 100,000 prescriptions

Two people die from faulty brake pedals, and the NTSB pulls cars off the road. Millions of lives destroyed, and hundreds die every day from the chemical poisons, which are never even winced at.

Hi Jim

I have no doubt that the Publication of Panorama led to increases in yellowcard reporting on Seroxat (Paxil) but one also has to look at the other consequences.

The Chart below shows that while Seroxat sales declined after the publication of Panorama the sales of the other brands actually increases.

The general view amongst people in my country is that Seroxat = bad .........all other SSRI = useful/harmless.

Interesting though it is to see the MHRA/FDA do something about Paxil/Seroxat it is so sad to see how little they do with the other brands which the public swallow with gay abandon.

Regards

see -

Prescribing of paroxetine was relatively steady between January 2001 and April 2002, but there was strong evidence that the number of paroxetine items prescribed per month declined after April 2002 [95% confidence interval (CI) December 2001 to June 2002] (P < 0.0001 for test of null hypothesis that difference between first and second slope = 0), so that the estimated monthly percentage change after this time was -1.87% (95% CI -2.06, -1.68; P < 0.0001 for test of null hypothesis that monthly percentage change = 0) (Figure 1A). There was no evidence that the rate of decline in prescribing of paroxetine changed again up to November 2004.

In contrast, prescribing of all other SSRIs combined (mainly fluoxetine and citalopram) increased by 1.15% (95% CI 1.01, 1.29; P ¡Ü 0.0001) per month between January 2001 and December 2003. After December 2003 the rate of increase declined (0.33%; 95% CI -0.39; 1.05; P = 0.4) (P = 0.03, for difference between slope 1 and 2) (Figure 1B), although the 95% CI for a join point at December 2003 was wide (April 2002 to June 2004).

http://www.ncbi. nlm.nih.gov/ pmc/articles/ PMC1884992/

> >> >> >> >> > Suspected adverse drug reactions to paroxetine (yellow-card reports) > > per 100 000 paroxetine prescriptions by year and month between 2001 > > and 2004. Arrows indicate dates of Panorama programmes (solid arrows) > > or regulatory communications (dashed arrows)> >> >> > Br J Clin Pharmacol. 2006 February; 61(2): 224--228.> >> > Published online 2005 October 27. doi: 10.1111/j.1365- 2125.2005. 02527.> >> >>

[Guest guest]

my thoughts exactely....

In memory of my father. Effexor (the loaded gun)

From: Antony Sandler <antonysandler@...>SSRI medications Sent: Wed, February 3, 2010 12:36:49 PMSubject: Re: Re: Seroxat ADR yellowcards =about 8 per 100,000 prescriptions

Two people die from faulty brake pedals, and the NTSB pulls cars off the road. Millions of lives destroyed, and hundreds die every day from the chemical poisons, which are never even winced at.

Hi Jim

I have no doubt that the Publication of Panorama led to increases in yellowcard reporting on Seroxat (Paxil) but one also has to look at the other consequences.

The Chart below shows that while Seroxat sales declined after the publication of Panorama the sales of the other brands actually increases.

The general view amongst people in my country is that Seroxat = bad .........all other SSRI = useful/harmless.

Interesting though it is to see the MHRA/FDA do something about Paxil/Seroxat it is so sad to see how little they do with the other brands which the public swallow with gay abandon.

Regards

see -

Prescribing of paroxetine was relatively steady between January 2001 and April 2002, but there was strong evidence that the number of paroxetine items prescribed per month declined after April 2002 [95% confidence interval (CI) December 2001 to June 2002] (P < 0.0001 for test of null hypothesis that difference between first and second slope = 0), so that the estimated monthly percentage change after this time was -1.87% (95% CI -2.06, -1.68; P < 0.0001 for test of null hypothesis that monthly percentage change = 0) (Figure 1A). There was no evidence that the rate of decline in prescribing of paroxetine changed again up to November 2004.

In contrast, prescribing of all other SSRIs combined (mainly fluoxetine and citalopram) increased by 1.15% (95% CI 1.01, 1.29; P ¡Ü 0.0001) per month between January 2001 and December 2003. After December 2003 the rate of increase declined (0.33%; 95% CI -0.39; 1.05; P = 0.4) (P = 0.03, for difference between slope 1 and 2) (Figure 1B), although the 95% CI for a join point at December 2003 was wide (April 2002 to June 2004).

http://www.ncbi. nlm.nih.gov/ pmc/articles/ PMC1884992/

> >> >> >> >> > Suspected adverse drug reactions to paroxetine (yellow-card reports) > > per 100 000 paroxetine prescriptions by year and month between 2001 > > and 2004. Arrows indicate dates of Panorama programmes (solid arrows) > > or regulatory communications (dashed arrows)> >> >> > Br J Clin Pharmacol. 2006 February; 61(2): 224--228.> >> > Published online 2005 October 27. doi: 10.1111/j.1365- 2125.2005. 02527.> >> >>

[Guest guest]

my thoughts exactely....

In memory of my father. Effexor (the loaded gun)

From: Antony Sandler <antonysandler@...>SSRI medications Sent: Wed, February 3, 2010 12:36:49 PMSubject: Re: Re: Seroxat ADR yellowcards =about 8 per 100,000 prescriptions

Two people die from faulty brake pedals, and the NTSB pulls cars off the road. Millions of lives destroyed, and hundreds die every day from the chemical poisons, which are never even winced at.

Hi Jim

I have no doubt that the Publication of Panorama led to increases in yellowcard reporting on Seroxat (Paxil) but one also has to look at the other consequences.

The Chart below shows that while Seroxat sales declined after the publication of Panorama the sales of the other brands actually increases.

The general view amongst people in my country is that Seroxat = bad .........all other SSRI = useful/harmless.

Interesting though it is to see the MHRA/FDA do something about Paxil/Seroxat it is so sad to see how little they do with the other brands which the public swallow with gay abandon.

Regards

see -

Prescribing of paroxetine was relatively steady between January 2001 and April 2002, but there was strong evidence that the number of paroxetine items prescribed per month declined after April 2002 [95% confidence interval (CI) December 2001 to June 2002] (P < 0.0001 for test of null hypothesis that difference between first and second slope = 0), so that the estimated monthly percentage change after this time was -1.87% (95% CI -2.06, -1.68; P < 0.0001 for test of null hypothesis that monthly percentage change = 0) (Figure 1A). There was no evidence that the rate of decline in prescribing of paroxetine changed again up to November 2004.

In contrast, prescribing of all other SSRIs combined (mainly fluoxetine and citalopram) increased by 1.15% (95% CI 1.01, 1.29; P ¡Ü 0.0001) per month between January 2001 and December 2003. After December 2003 the rate of increase declined (0.33%; 95% CI -0.39; 1.05; P = 0.4) (P = 0.03, for difference between slope 1 and 2) (Figure 1B), although the 95% CI for a join point at December 2003 was wide (April 2002 to June 2004).

http://www.ncbi. nlm.nih.gov/ pmc/articles/ PMC1884992/

> >> >> >> >> > Suspected adverse drug reactions to paroxetine (yellow-card reports) > > per 100 000 paroxetine prescriptions by year and month between 2001 > > and 2004. Arrows indicate dates of Panorama programmes (solid arrows) > > or regulatory communications (dashed arrows)> >> >> > Br J Clin Pharmacol. 2006 February; 61(2): 224--228.> >> > Published online 2005 October 27. doi: 10.1111/j.1365- 2125.2005. 02527.> >> >>

[Guest guest]

Hi ,

I would say my just my observation. I'm certainly not infallible and

would hate for anyone to take any of these poisons

thinking one was better than another since none apparently work any

better than placebo anyways.

I looked on this website http://www.cchrint.org/psychdrugdangers/

The site lists FDA adverse event reports from 2004 to 2006.

Adverse events reporting from 2004 to 2006 and got 18,846

Individual Safety Reports on Paxil/Seroxat

For Prozac during that time 2,290 Individual Safety Reports.

Effexor during that time 4,606 Individual Safety Reports.

It's only a couple of years but that is a huge difference in adverse

events.

It's very possible that all of the drugs are just as liable to cause

death/suicide/homicide/withdrawals

but for some reason have not been reported or no attention has gone to

them in the media.

Maybe the MHRA/FDA regulatory actions play some role. I honestly don't

know. Maybe

Panorama caused the attention on Paxil/Seroxat and that started the

ball rolling.

But if you were to look at www.ssristories.com you get a ton of

press on Prozac and Paxil/Seroxat equally whilst

the other antidepressants do not have near the same press. Effexor

seems to be in the 3rd place as far as

press involving the drug in mayhem. None of this data is the whole

truth obviously.

All the antidepressants are a nasty toxic scourge on humanity but in

the collection of data I can find to hand

Paxil "appears" to be worse by far than the rest.

Best,

Jim

On 2/3/2010 4:40 PM, jeremy9282 wrote:

Hi Jim

I was wondering on what you base your personal opinion that

Paxil/Seroxat is the worse?

I'm very concerned that the (UK) media, led by Panorama have

broadcast that view, when it is clear that the producers of the

programme chose to target the GSK product, even though journalists like

Jofre are on record as saying all the brands have similar problems.

check her out here - http://coventryuniversity.podbean.com/2007/11/01/one-woman-a-multinational-and-a-victory-shelley-jofre-panorama/

Could the adverse publicity surrounding Paxil/Seroxat have made

the total SSRI situation worse?

see -http://www.tuesday1st.blogspot.com/

Regards

> > > >

> > > >

> > > >

> > > >

> > > > Suspected adverse drug reactions to paroxetine

(yellow-card reports)

> > > > per 100 000 paroxetine prescriptions by year and

month between 2001

> > > > and 2004. Arrows indicate dates of Panorama

programmes (solid arrows)

> > > > or regulatory communications (dashed arrows)

> > > >

> > > >

> > > > Br J Clin Pharmacol. 2006 February; 61(2): 224--228.

> > > >

> > > > Published online 2005 October 27. doi:

10.1111/j.1365-2125.2005.02527.

> > > >

> > > >

> > >

> >

> >

> >

> >

>

[Guest guest]

Hi ,

I would say my just my observation. I'm certainly not infallible and

would hate for anyone to take any of these poisons

thinking one was better than another since none apparently work any

better than placebo anyways.

I looked on this website http://www.cchrint.org/psychdrugdangers/

The site lists FDA adverse event reports from 2004 to 2006.

Adverse events reporting from 2004 to 2006 and got 18,846

Individual Safety Reports on Paxil/Seroxat

For Prozac during that time 2,290 Individual Safety Reports.

Effexor during that time 4,606 Individual Safety Reports.

It's only a couple of years but that is a huge difference in adverse

events.

It's very possible that all of the drugs are just as liable to cause

death/suicide/homicide/withdrawals

but for some reason have not been reported or no attention has gone to

them in the media.

Maybe the MHRA/FDA regulatory actions play some role. I honestly don't

know. Maybe

Panorama caused the attention on Paxil/Seroxat and that started the

ball rolling.

But if you were to look at www.ssristories.com you get a ton of

press on Prozac and Paxil/Seroxat equally whilst

the other antidepressants do not have near the same press. Effexor

seems to be in the 3rd place as far as

press involving the drug in mayhem. None of this data is the whole

truth obviously.

All the antidepressants are a nasty toxic scourge on humanity but in

the collection of data I can find to hand

Paxil "appears" to be worse by far than the rest.

Best,

Jim

On 2/3/2010 4:40 PM, jeremy9282 wrote:

Hi Jim

I was wondering on what you base your personal opinion that

Paxil/Seroxat is the worse?

I'm very concerned that the (UK) media, led by Panorama have

broadcast that view, when it is clear that the producers of the

programme chose to target the GSK product, even though journalists like

Jofre are on record as saying all the brands have similar problems.

check her out here - http://coventryuniversity.podbean.com/2007/11/01/one-woman-a-multinational-and-a-victory-shelley-jofre-panorama/

Could the adverse publicity surrounding Paxil/Seroxat have made

the total SSRI situation worse?

see -http://www.tuesday1st.blogspot.com/

Regards

> > > >

> > > >

> > > >

> > > >

> > > > Suspected adverse drug reactions to paroxetine

(yellow-card reports)

> > > > per 100 000 paroxetine prescriptions by year and

month between 2001

> > > > and 2004. Arrows indicate dates of Panorama

programmes (solid arrows)

> > > > or regulatory communications (dashed arrows)

> > > >

> > > >

> > > > Br J Clin Pharmacol. 2006 February; 61(2): 224--228.

> > > >

> > > > Published online 2005 October 27. doi:

10.1111/j.1365-2125.2005.02527.

> > > >

> > > >

> > >

> >

> >

> >

> >

>

[Guest guest]

Hi ,

I would say my just my observation. I'm certainly not infallible and

would hate for anyone to take any of these poisons

thinking one was better than another since none apparently work any

better than placebo anyways.

I looked on this website http://www.cchrint.org/psychdrugdangers/

The site lists FDA adverse event reports from 2004 to 2006.

Adverse events reporting from 2004 to 2006 and got 18,846

Individual Safety Reports on Paxil/Seroxat

For Prozac during that time 2,290 Individual Safety Reports.

Effexor during that time 4,606 Individual Safety Reports.

It's only a couple of years but that is a huge difference in adverse

events.

It's very possible that all of the drugs are just as liable to cause

death/suicide/homicide/withdrawals

but for some reason have not been reported or no attention has gone to

them in the media.

Maybe the MHRA/FDA regulatory actions play some role. I honestly don't

know. Maybe

Panorama caused the attention on Paxil/Seroxat and that started the

ball rolling.

But if you were to look at www.ssristories.com you get a ton of

press on Prozac and Paxil/Seroxat equally whilst

the other antidepressants do not have near the same press. Effexor

seems to be in the 3rd place as far as

press involving the drug in mayhem. None of this data is the whole

truth obviously.

All the antidepressants are a nasty toxic scourge on humanity but in

the collection of data I can find to hand

Paxil "appears" to be worse by far than the rest.

Best,

Jim

On 2/3/2010 4:40 PM, jeremy9282 wrote:

Hi Jim

I was wondering on what you base your personal opinion that

Paxil/Seroxat is the worse?

I'm very concerned that the (UK) media, led by Panorama have

broadcast that view, when it is clear that the producers of the

programme chose to target the GSK product, even though journalists like

Jofre are on record as saying all the brands have similar problems.

check her out here - http://coventryuniversity.podbean.com/2007/11/01/one-woman-a-multinational-and-a-victory-shelley-jofre-panorama/

Could the adverse publicity surrounding Paxil/Seroxat have made

the total SSRI situation worse?

see -http://www.tuesday1st.blogspot.com/

Regards

> > > >

> > > >

> > > >

> > > >

> > > > Suspected adverse drug reactions to paroxetine

(yellow-card reports)

> > > > per 100 000 paroxetine prescriptions by year and

month between 2001

> > > > and 2004. Arrows indicate dates of Panorama

programmes (solid arrows)

> > > > or regulatory communications (dashed arrows)

> > > >

> > > >

> > > > Br J Clin Pharmacol. 2006 February; 61(2): 224--228.

> > > >

> > > > Published online 2005 October 27. doi:

10.1111/j.1365-2125.2005.02527.

> > > >

> > > >

> > >

> >

> >

> >

> >

>

[Guest guest]

Hi ,

I would say my just my observation. I'm certainly not infallible and

would hate for anyone to take any of these poisons

thinking one was better than another since none apparently work any

better than placebo anyways.

I looked on this website http://www.cchrint.org/psychdrugdangers/

The site lists FDA adverse event reports from 2004 to 2006.

Adverse events reporting from 2004 to 2006 and got 18,846

Individual Safety Reports on Paxil/Seroxat

For Prozac during that time 2,290 Individual Safety Reports.

Effexor during that time 4,606 Individual Safety Reports.

It's only a couple of years but that is a huge difference in adverse

events.

It's very possible that all of the drugs are just as liable to cause

death/suicide/homicide/withdrawals

but for some reason have not been reported or no attention has gone to

them in the media.

Maybe the MHRA/FDA regulatory actions play some role. I honestly don't

know. Maybe

Panorama caused the attention on Paxil/Seroxat and that started the

ball rolling.

But if you were to look at www.ssristories.com you get a ton of

press on Prozac and Paxil/Seroxat equally whilst

the other antidepressants do not have near the same press. Effexor

seems to be in the 3rd place as far as

press involving the drug in mayhem. None of this data is the whole

truth obviously.

All the antidepressants are a nasty toxic scourge on humanity but in

the collection of data I can find to hand

Paxil "appears" to be worse by far than the rest.

Best,

Jim

On 2/3/2010 4:40 PM, jeremy9282 wrote:

Hi Jim

I was wondering on what you base your personal opinion that

Paxil/Seroxat is the worse?

I'm very concerned that the (UK) media, led by Panorama have

broadcast that view, when it is clear that the producers of the

programme chose to target the GSK product, even though journalists like

Jofre are on record as saying all the brands have similar problems.

check her out here - http://coventryuniversity.podbean.com/2007/11/01/one-woman-a-multinational-and-a-victory-shelley-jofre-panorama/

Could the adverse publicity surrounding Paxil/Seroxat have made

the total SSRI situation worse?

see -http://www.tuesday1st.blogspot.com/

Regards

> > > >

> > > >

> > > >

> > > >

> > > > Suspected adverse drug reactions to paroxetine

(yellow-card reports)

> > > > per 100 000 paroxetine prescriptions by year and

month between 2001

> > > > and 2004. Arrows indicate dates of Panorama

programmes (solid arrows)

> > > > or regulatory communications (dashed arrows)

> > > >

> > > >

> > > > Br J Clin Pharmacol. 2006 February; 61(2): 224--228.

> > > >

> > > > Published online 2005 October 27. doi:

10.1111/j.1365-2125.2005.02527.

> > > >

> > > >

> > >

> >

> >

> >

> >

>